Amplitude Surgical Announces Its Results for the First Half of 2022-23

Sales of €45.2 Million and EBITDA of €11.7 Million - Seite 2

General & Administrative costs

6.2

5.6

10.7%

Research & Development costs

0.8

0.9

-14.2%

EBITDA

 

11.7

10.2

14.0%

as a % of sales

 

25.8%

25.4%

+35 bps

Recurring operating profit/loss

4.9

2.9

 

Non-recurring operating income and expenses

-1.0

-0.3

 

Operating profit/loss

3.9

2.6

 

Financial profit/loss

-6.9

-4.4

 

Current and deferred tax

-0.3

-0.4

 

Profit/loss from discontinued activities, after tax

-0,9

-0.8

 

Net profit/loss - Group share

-4.2

-2.8

 

 

 

December 31,
2022

June 30, 2022

 

Net financial debt

128.3

118.0

 

Cash position at end of period

11.0